ASH: Roche offers glimpse of Columvi-Polivy combo's early lymphoma data as phase 3 kicks off

Roche’s blood cancer portfolio is booming with new life thanks to the antibody-drug conjugate Polivy and bispecifics. Now, the company is offering a look at early-phase data for two combinations of those drugs that support two phase 3 trials in diffuse large B-cell lymphoma (DLBCL).